CSS LLC’s Standard BioTools LAB Stock Holding History

CSS LLC’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-30,000	Closed	-$151K	–	640
2017 Q3	$151K	Buy	+30,000	New	+$126K	0.01%	522
2017 Q2	–	Sell	-10,000	Closed	-$57K	–	667
2017 Q1	$57K	Hold	10,000	–	–	﹤0.01%	593
2016 Q4	$73K	Buy	+10,000	New	+$62.8K	﹤0.01%	630

Other funds holding LAB

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

CSS LLC's LAB Position: Q1 2018 in Review

CSS LLC sold out of Standard BioTools (LAB) in Q1 2018, closing a stake of 5,080 shares — an estimated $30K sold.

CSS LLC first reported a position in LAB in Q4 2017 and held it in 1 quarter. The position peaked at $30K in Q4 2017. 84 funds tracked by Wall St. Rank hold LAB as of Q1 2018.

CSS LLC reported no remaining Standard BioTools position as of Q1 2018 after selling out during the quarter.
CSS LLC sold 5,080 Standard BioTools shares in Q1 2018, an estimated $30K.
CSS LLC first reported a position in Standard BioTools in Q4 2017 and held it in 1 quarter.
CSS LLC's Standard BioTools position peaked at $30K in Q4 2017.
84 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2018.

Based on CSS LLC's 13F filing for Q1 2018, filed 15 May 2018.